Quick Answer
Olema Pharmaceuticals, Inc. reported Stockholders Equity of $478.56 million for the year ending 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +17.0% in Stockholders Equity from 2024 to 2025.
- This data is from Olema Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$11.65 million | Q2 2020: -$13.95 million | Q3 2020: -$22.96 million | Q1 2021: $326.02 million | Q2 2021: $314.08 million | Q3 2021: $300.89 million | Q1 2022: $265.09 million | Q2 2022: $236.28 million | Q3 2022: $217.70 million | Q1 2023: $174.98 million | Q2 2023: $161.58 million | Q3 2023: $275.13 million | Q1 2024: $236.32 million | Q2 2024: $227.16 million | Q3 2024: $198.91 million | Q1 2025: $383.45 million | Q2 2025: $345.24 million | Q3 2025: $307.49 million.
- Over the full 8 years of available data (2018 to 2025), Olema Pharmaceuticals, Inc.'s Stockholders Equity has grown by 5,799.2%.
- Historical annual values: Fiscal year 2025: $478.56 million | Fiscal year 2024: $408.96 million | Fiscal year 2023: $253.90 million | Fiscal year 2022: $197.55 million | Fiscal year 2021: $284.57 million | Fiscal year 2020: $338.14 million | Fiscal year 2019: -$10.59 million | Fiscal year 2018: -$8.40 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: